Pharmadil
ActiveSummary
The computed 12-month bankruptcy probability of Pharmadil is 7.5% (elevated). For Pharmadil, one filing cycle of the annual accounts is missing. The 2024 annual accounts show negative equity (-€88,047) and a net result of -€69,128. Equity is shrinking by ~62% per year across the filed fiscal years. Its solvency ranks better than 8% of 9655 sector peers (fiscal year 2024). The company has been active since 2014 and the Belgian State Gazette contains no insolvency or warning signals.
History
Acts, filings and financial milestones
2024
13-11
NBB filing
Annual accounts filed
fiscal year 2024 · abbreviated schema · 13 days late
31-03
Financial
Weakest financial yearnet -€69,128
Net result drops to -€69,128, the lowest in the series.
2023
30-10
NBB filing
Annual accounts filed
fiscal year 2023 · abbreviated schema
2022
10-11
NBB filing
Annual accounts filed
fiscal year 2022 · abbreviated schema · 10 days late
31-03
Financial
Back to profitnet €4,116
Net result €4,116 after one loss-making year.
2021
16-11
NBB filing
Annual accounts filed
fiscal year 2021 · abbreviated schema · 16 days late
2020
26-11
NBB filing
Annual accounts filed
fiscal year 2020 · abbreviated schema · 26 days late
2019
10-10
NBB filing
Annual accounts filed
fiscal year 2019 · abbreviated schema
2018
23-10
NBB filing
Annual accounts filed
fiscal year 2018 · abbreviated schema
2017
15-09
NBB filing
Annual accounts filed
fiscal year 2017 · abbreviated schema
2016
06-09
NBB filing
Annual accounts filed
fiscal year 2016 · abbreviated schema
2015
06-10
NBB filing
Annual accounts filed
fiscal year 2015 · abbreviated schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
0 of 4 acts read
About the unread acts
We know of 4 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.